Chrysoula Vraka

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 9

Top Venues

Pharmaceuticals (Basel, Switzerland)

Cancers

Current oncology (Toronto, Ont.)

Scientific reports

Medical University of Vienna

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Medical University of Vienna Mar 13 2016

Austria

Head of Biolabs (Radiopharmacy and Experimental Nuclear Medicine) :: Department of Biomedical Imaging and Image-guided Therapy

Publications

Andreas Hahn, Murray Bruce Reed, Chrysoula Vraka, Godber Mathis Godbersen, Sebastian Klug, Arkadiusz Komorowski, Pia Falb, Lukas Nics, Tatjana Traub-Weidinger, Marcus Hacker, Rupert Lanzenberger
High-temporal resolution functional PET/MRI reveals coupling between human metabolic and hemodynamic brain response. European journal of nuclear medicine and molecular imaging (2023)
Karsten Bamminger, Verena Pichler, Chrysoula Vraka, Tina Nehring, Katharina Pallitsch, Barbara Lieder, Marcus Hacker, Wolfgang Wadsak
On the Road towards Small-Molecule Programmed Cell Death 1 Ligand 1 Positron Emission Tomography Tracers: A Ligand-Based Drug Design Approach. Pharmaceuticals (Basel, Switzerland) 16 (7) (2023)
Chrysoula Vraka, Matej Murgaš, Lucas Rischka, Barbara Katharina Geist, Rupert Lanzenberger, Gregor Gryglewski, Thomas Zenz, Wolfgang Wadsak, Markus Mitterhauser, Marcus Hacker, Cécile Philippe, Verena Pichler
Simultaneous radiomethylation of [ 11 C]harmine and [ 11 C]DASB and kinetic modeling approach for serotonergic brain imaging in the same individual. Scientific reports 12 (1) (2022)
Eva-Maria Klebermass, Mahshid Mahmudi, Barbara Katharina Geist, Verena Pichler, Chrysoula Vraka, Theresa Balber, Anne Miller, Arvand Haschemi, Helmut Viernstein, Nataliya Rohr-Udilova, Marcus Hacker, Markus Mitterhauser
If It Works, Don't Touch It? A Cell-Based Approach to Studying 2-[18F]FDG Metabolism. Pharmaceuticals (Basel, Switzerland) 14 (9) (2021)
Sazan Rasul, Tim Wollenweber, Lucia Zisser, Elisabeth Kretschmer-Chott, Bernhard Grubmüller, Gero Kramer, Shahrokh F Shariat, Harald Eidherr, Markus Mitterhauser, Chrysoula Vraka, Werner Langsteger, Marcus Hacker, Alexander R Haug
Response and Toxicity to the Second Course of 3 Cycles of 177Lu-PSMA Therapy Every 4 Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer. Cancers 13 (10) (2021)
Mahlegha Ghavami, Chrysoula Vraka, Virginie Hubert, Helga Schachner, Karsten Bamminger, Marcus Hacker, Renate Kain, Mehdi Forouzandeh Moghadam
Radiolabeled HER2-directed exosomes exhibit improved cell targeting and specificity. Nanomedicine (London, England) 16 (7) (2021)
Tim Wollenweber, Lucia Zisser, Elisabeth Kretschmer-Chott, Michael Weber, Bernhard Grubmüller, Gero Kramer, Shahrokh F Shariat, Markus Mitterhauser, Stefan Schmitl, Chrysoula Vraka, Alexander R Haug, Marcus Hacker, Markus Hartenbach, Sazan Rasul
Renal and Salivary Gland Functions after Three Cycles of PSMA-617 Therapy Every Four Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer. Current oncology (Toronto, Ont.) 28 (5) (2021)
Marius Ozenil, Jonas Aronow, Daniela Piljak, Chrysoula Vraka, Wolfgang Holzer, Helmut Spreitzer, Wolfgang Wadsak, Marcus Hacker, Verena Pichler
Synthesis, Biological, and Computational Evaluation of Antagonistic, Chiral Hydrobenzoin Esters of Arecaidine Targeting mAChR M1. Pharmaceuticals (Basel, Switzerland) 13 (12) (2020)
Chrysoula Vraka, Verena Pichler, Neydher Berroterán-Infante, Tim Wollenweber, Anna Pillinger, Maximilian Hohensinner, Lukas Fetty, Dietrich Beitzke, Xiang Li, Cecile Philippe, Katharina Pallitsch, Markus Mitterhauser, Marcus Hacker, Wolfgang Wadsak
Optimization of the Automated Synthesis of [11C]mHED-Administered and Apparent Molar Activities. Pharmaceuticals (Basel, Switzerland) 12 (1) (2019)

Chrysoula Vraka.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Chrysoula Vraka